ClinicalTrials.gg
CompletedNCT02124161Updated Jul 1, 2016Results posted

Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

A Phase 4 interventional study of 13-valent pneumococcal conjugate vaccine and Seasonal Inactivated Influenza Vaccine in PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, sponsored by Pfizer. Completed at 44 sites in United States. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-07-01.

Sponsored by Pfizer · Phase 4, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
882
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Influenza, Human by Pfizer — 1 open to participants now, 2 under way, none of them phase 3. Influenza, Human · Pfizer.

Enrollment
6th of 11
882 · median 882
Started
2014
the only one that year
Phase 4
Only one
of the 15
Registered
2nd of 15
by date

Among the 15 studies in Influenza, Human by Pfizer, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2014, is the only one in phase 4, and was the 2nd registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

1 of the 15 studies in Influenza, Human by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 50 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Influenza, Human by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the immunogenicity and safety of 13-valent pneumococcal polysaccharide vaccine when given concomitantly with seasonal inactivated influenza vaccine to adults 50 years and older who have previously received 23-valent pneumococcal polysaccharide vaccine.

03

Conditions studied

  • PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE

Browse trials for

Keywords

  • Pneumococcal polysaccharide vaccine
  • 13-valent pneumococcal conjugate vaccine
  • invasive pneumococcal disease
  • flu vaccine
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Evidence of a personally signed and dated document (ICD) indicating that the subject has been informed of all pertinent aspects of the study.
  2. Male or female adults 50 years of age or older.
  3. Documented vaccination with 1 or more prior doses of 23vPS, the last given at least 1 year prior to study enrollment.
  4. Negative urine pregnancy test for all female subjects who are of child bearing potential.

Exclusion criteria

Exclusion Criteria:

  1. Previous vaccination with Prevnar®, Prevnar 13®, or any other pneumococcal conjugate vaccine.
  2. History of severe adverse reactions associated with any vaccine or vaccine-related component.
  3. Allergic to egg proteins (egg or egg products) and chicken proteins.
  4. History of Guillain-Barré syndrome.
  5. Vaccination with any influenza vaccine within 6 months (182 days) before investigational product administration.
  6. Documented S pneumoniae infection within the past 5 years before investigational product administration.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
882 participants (actual)

Study arms

  • Other
    13vPnC+SIIV/Placebo

    Biological: 13-valent pneumococcal conjugate vaccine · Biological: Seasonal Inactivated Influenza Vaccine · Other: Placebo

  • Other
    Placebo+SIIV/13vPnC

    Other: Placebo · Biological: Seasonal Inactivated Influenza Vaccine · Biological: 13-valent pneumococcal conjugate vaccine

Interventions

  • One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.

    Also known as: 13vPnC

  • BiologicalSeasonal Inactivated Influenza Vaccine

    One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.

    Also known as: SIIV

  • OtherPlacebo

    One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.

  • OtherPlacebo

    One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.

  • BiologicalSeasonal Inactivated Influenza Vaccine

    One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.

    Also known as: SIIV

  • One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.

    Also known as: 13vPnC

06

What researchers measure

Primary outcomes

  1. Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes

    Serotype-specific OPA GMTs for each of the 13 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were logarithmically transformed for analysis. Confidence intervals (CIs) for GMT were back-transformed based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here, "number of participants analyzed" signifies the participants who were evaluable at this timepoint and "n" signifies participants with a determinate OPA titer to the given serotype.

    Time frame: 1 month after Vaccination 1 for 13vPnC+QIV/Placebo, 1 Month After Vaccination 2 for Placebo+QIV/13vPnC

  2. Hemagglutination Inhibition Assay (HAI) Geometric Mean Titers (GMTs) for Each Influenza Virus Strain in Quadrivalent Influenza Vaccine (QIV)

    HAI GMTs were computed for assay titers collected 1 month after Vaccination 1 by vaccine sequence for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). CIs were back-transformations of a CI based on the Student t distribution for the mean logarithm of the titers. HAI GMTs were calculated using all participants with available data for the specified blood draw. Here, "number of participants analyzed" signifies participants with a determinate HAI titer to the given strain.

    Time frame: 1 month after Vaccination 1

  3. Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 1

    An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).

    Time frame: Within 28 to 42 days after Vaccination 1

  4. Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 2

    An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).

    Time frame: Within 28 to 42 days after Vaccination 2

  5. Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After 13vPnC Vaccination

    An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).

    Time frame: Baseline (Vaccination 1) up to 28 to 42 Days after Vaccination 2

  6. Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) at the 6-Month Follow-up

    An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).

    Time frame: Within 168 to 196 days after Vaccination 2

Secondary outcomes

  1. Percentage of Participants Achieving Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibody Titer Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ)

    Percentage of participants achieving predefined OPA antibody titer \>= LLOQ for each of the 13 pneumococcal serotypes (LLOQs for each serotype OPA were set as- serotype 1: 18; serotype 3: 12; serotype 4: 21; serotype 5: 29; serotype 6A: 37; serotype 6B: 43; serotype 7F: 210; serotype 9V: 345; serotype 14: 35; serotype 18C: 31; serotype 19A: 18; serotype 19F: 48; and serotype 23F: 13) determined in blood samples of all participants were calculated. Exact, 2-sided 95% CIs based on the observed percentage of participants were determined by using Clopper and Pearson method. OPA titers were calculated using all participants with available data from 1 month after 13vPnC vaccination blood draw. Here, "number of participants analyzed" signifies the participants who were evaluable at this timepoint and "n" signifies participants with valid and determinate assay results to the specified serotype.

    Time frame: 1 Month After Vaccination 1 for 13vPnC+QIV/Placebo, 1 month after Vaccination 2 for Placebo+QIV/13vPnC

  2. Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 1 to Immediately Before 13vPnC Vaccination 1

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 1 to before Vaccination 1 were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 1 and 1 month after Vaccination 1 blood draws. Here, "n" signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 1 were analyzed.

    Time frame: Immediately before Vaccination 1, 1 month after Vaccination 1

  3. Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 2 to Immediately Before 13vPnC Vaccination 2

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 2 to before Vaccination 2 (1 month after Vaccination 1) were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 2 and 1 month after Vaccination 2 blood draws. Here, "number of participants analyzed" signifies total participants who were evaluable at this timepoint and "n" signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 2 were analyzed.

    Time frame: Immediately before Vaccination 2, 1 month after Vaccination 2

  4. Percentage of Participants Achieving Seroconversion in Hemagglutination Inhibition Assay (HAI) Titers

    Percentage of participants achieving seroconversion in HAI titers was defined as the percentage of participants with either before Vaccination 1 (pre-vaccination 1) HAI titer less than \<1:10 and after Vaccination 1 (post-vaccination 1) HAI titer \>=1:40 or before Vaccination 1 (pre-vaccination 1) HAI titer \>=1:10 and a minimum 4-fold rise in after Vaccination 1 (post-vaccination 1) HAI antibody titer with respect to before Vaccination 1 (pre-vaccination) titer for influenza virus strains. Here, "number of participants analyzed" signifies the participants who were evaluable at this timepoint.

    Time frame: Immediately before Vaccination 1, 1 month after Vaccination 1

  5. Geometric Mean Fold Rise (GMFR) in Hemagglutination Inhibition Assay (HAI) 1 Month After Vaccination 1 to Immediately Before Vaccination 1

    Fold rise 1 month after Vaccination 1 to before Vaccination 1 was calculated for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). GMFRs were calculated using all participants with available data from both the specified blood draws. CI for the GMFRs were back transformations of a CI based on the Student t distribution for mean fold rise. Here, "number of participants analyzed" signifies participants with valid and determinate assay results for specified strain at both the specified blood draws.

    Time frame: Immediately before Vaccination 1, 1 month after Vaccination 1

07

Results

Posted Jul 1, 2016

Participant flow

Participant flow — Overall Study
Milestone13vPnC+QIV/PlaceboPlacebo+QIV/13vPnC
Started441441
Vaccination 1439437
Vaccination 2431432
Completed425426
Not completed1615
Withdrew: Other unspecified01
Withdrew: Death10
Withdrew: Protocol violation21
Withdrew: Withdrawal by subject12
Withdrew: Adverse event20
Withdrew: Does not meet entrance criteria23
Withdrew: No longer meets eligibility criteria54
Withdrew: Lost to follow-up34

Outcome measures

PrimarySerotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes

Serotype-specific OPA GMTs for each of the 13 pneumococcal common serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were logarithmically transformed for analysis. Confidence intervals (CIs) for GMT were back-transformed based on the Student t distribution for the mean logarithm of the titers. GMTs were calculated using all participants with available data for the specified blood draw. Here, "number of participants analyzed" signifies the participants who were evaluable at this timepoint and "n" signifies participants with a determinate OPA titer to the given serotype.

Time frame:
1 month after Vaccination 1 for 13vPnC+QIV/Placebo, 1 Month After Vaccination 2 for Placebo+QIV/13vPnC
Reported as:
Geometric mean · titer
Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes
titer13vPnC+QIV/PlaceboPlacebo+QIV/13vPnC
Serotype 1 (n= 419, 417)75 (65.0 to 87.0)83 (71.1 to 96.1)
Serotype 3 (n= 422, 418)41 (36.2 to 46)49 (43.6 to 55.3)
Serotype 4 (n= 412, 417)587 (489.9 to 702.5)824 (692.2 to 980)
Serotype 5 (n= 423, 414)97 (83.8 to 111.7)101 (86.6 to 117.2)
Serotype 6A (n= 420, 415)953 (805.7 to 1126.3)1413 (1203.3 to 1659.4)
Serotype 6B (n= 414, 405)867 (722.3 to 1039.6)1041 (860.5 to 1260)
Serotype 7F (n= 424, 419)651 (582.4 to 728)670 (599.7 to 748.5)
Serotype 9V (n= 419, 415)699 (613.7 to 797.2)838 (734.2 to 957.5)
Serotype 14 (n= 421, 416)574 (496.8 to 663)760 (665.6 to 868)
Serotype 18C (n= 420, 414)713 (598.9 to 849.9)865 (726.4 to 1030.5)
Serotype 19A (n= 425, 419)337 (294.9 to 384.6)390 (344.4 to 441.1)
Serotype 19F (n= 423, 416)324 (274.8 to 382.5)360 (302.7 to 427.9)
Serotype 23F (n= 421, 417)278 (223.9 to 344.7)364 (294.3 to 451.3)
Statistical analysis
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 0.9 · 95% CI 0.74 to 1.12
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 0.8 · 95% CI 0.70 to 0.98
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 0.7 · 95% CI 0.55 to 0.91
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 1.0 · 95% CI 0.78 to 1.18
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 0.7 · 95% CI 0.53 to 0.85
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 0.8 · 95% CI 0.64 to 1.08
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 1.0 · 95% CI 0.83 to 1.14
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 0.8 · 95% CI 0.69 to 1.0
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 0.8 · 95% CI 0.62 to 0.92
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 0.8 · 95% CI 0.64 to 1.06
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 0.9 · 95% CI 0.72 to 1.04
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 0.9 · 95% CI 0.71 to 1.14
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 0.8 · 95% CI 0.56 to 1.03
PrimaryHemagglutination Inhibition Assay (HAI) Geometric Mean Titers (GMTs) for Each Influenza Virus Strain in Quadrivalent Influenza Vaccine (QIV)

HAI GMTs were computed for assay titers collected 1 month after Vaccination 1 by vaccine sequence for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). CIs were back-transformations of a CI based on the Student t distribution for the mean logarithm of the titers. HAI GMTs were calculated using all participants with available data for the specified blood draw. Here, "number of participants analyzed" signifies participants with a determinate HAI titer to the given strain.

Time frame:
1 month after Vaccination 1
Reported as:
Geometric mean · titer
Hemagglutination Inhibition Assay (HAI) Geometric Mean Titers (GMTs) for Each Influenza Virus Strain in Quadrivalent Influenza Vaccine (QIV)
titer13vPnC+QIV/PlaceboPlacebo+QIV/13vPnC
Strain: A/H1N1115 (104.0 to 126.8)113 (101.6 to 124.7)
Strain: A/H3N2226 (206.1 to 248.5)196 (178.0 to 216.1)
Strain: B/Brisbane28 (25.7 to 31.0)26 (23.7 to 28.7)
Strain: B/Massachusetts45 (41.0 to 50.3)43 (39.1 to 48.2)
Statistical analysis
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 1.0 · 95% CI 0.88 to 1.18
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 1.2 · 95% CI 1.01 to 1.32
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 1.1 · 95% CI 0.95 to 1.24
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Gmt ratio: 1.0 · 95% CI 0.90 to 1.21
PrimaryPercentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 1

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).

Time frame:
Within 28 to 42 days after Vaccination 1
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 1
percentage of participants13vPnC+QIV/PlaceboPlacebo+QIV/13vPnC
AE15.311.9
SAE1.40
PrimaryPercentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 2

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).

Time frame:
Within 28 to 42 days after Vaccination 2
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After Vaccination 2
percentage of participants13vPnC+QIV/PlaceboPlacebo+QIV/13vPnC
AE10.412.5
SAE1.61.4
PrimaryPercentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After 13vPnC Vaccination

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).

Time frame:
Baseline (Vaccination 1) up to 28 to 42 Days after Vaccination 2
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) After 13vPnC Vaccination
percentage of participants13vPnC+QIV/PlaceboPlacebo+QIV/13vPnC
AE15.312.5
SAE1.41.4
Statistical analysis
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Percentage difference: 2.8 · 95% CI -1.9 to 7.4
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Percentage difference: -0.0 · 95% CI -1.8 to 1.7
PrimaryPercentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) at the 6-Month Follow-up

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. AEs included both SAEs and non-serious adverse events (Non-SAEs).

Time frame:
Within 168 to 196 days after Vaccination 2
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment--Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) at the 6-Month Follow-up
percentage of participants13vPnC+QIV/PlaceboPlacebo+QIV/13vPnC
AE2.52.7
SAE1.11.4
SecondaryPercentage of Participants Achieving Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibody Titer Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ)

Percentage of participants achieving predefined OPA antibody titer \>= LLOQ for each of the 13 pneumococcal serotypes (LLOQs for each serotype OPA were set as- serotype 1: 18; serotype 3: 12; serotype 4: 21; serotype 5: 29; serotype 6A: 37; serotype 6B: 43; serotype 7F: 210; serotype 9V: 345; serotype 14: 35; serotype 18C: 31; serotype 19A: 18; serotype 19F: 48; and serotype 23F: 13) determined in blood samples of all participants were calculated. Exact, 2-sided 95% CIs based on the observed percentage of participants were determined by using Clopper and Pearson method. OPA titers were calculated using all participants with available data from 1 month after 13vPnC vaccination blood draw. Here, "number of participants analyzed" signifies the participants who were evaluable at this timepoint and "n" signifies participants with valid and determinate assay results to the specified serotype.

Time frame:
1 Month After Vaccination 1 for 13vPnC+QIV/Placebo, 1 month after Vaccination 2 for Placebo+QIV/13vPnC
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA) Antibody Titer Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ)
percentage of participants13vPnC+QIV/PlaceboPlacebo+QIV/13vPnC
Serotype 1 (n= 419, 417)77.3 (73.0 to 81.3)80.1 (75.9 to 83.8)
Serotype 3 (n= 422, 418)79.4 (75.2 to 83.1)83.7 (79.8 to 87.1)
Serotype 4 (n= 412, 417)88.6 (85.1 to 91.5)92.1 (89.1 to 94.5)
Serotype 5 (n= 423, 414)74.5 (70.0 to 78.6)72.7 (68.1 to 76.9)
Serotype 6A (n= 420, 415)90.5 (87.3 to 93.1)94.2 (91.5 to 96.3)
Serotype 6B (n= 414, 405)85.0 (81.2 to 88.3)86.4 (82.7 to 89.6)
Serotype 7F (n= 424, 419)82.3 (78.3 to 85.8)83.5 (79.6 to 87.0)
Serotype 9V (n= 419, 415)65.2 (60.4 to 69.7)71.3 (66.7 to 75.6)
Serotype 14 (n= 421, 416)91.4 (88.4 to 93.9)95.2 (92.7 to 97.0)
Serotype 18C (n= 420, 414)88.8 (85.4 to 91.7)91.3 (88.2 to 93.8)
Serotype 19A (n= 425, 419)95.5 (93.1 to 97.3)97.4 (95.4 to 98.7)
Serotype 19F (n= 423, 416)79.9 (75.8 to 83.6)79.6 (75.4 to 83.3)
Serotype 23F (n= 421, 417)80.3 (76.2 to 84.0)84.2 (80.3 to 87.5)
Statistical analysis
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.333 · Percentage difference: -2.8 · 95% CI -8.3 to 2.8
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.105 · Percentage difference: -4.3 · 95% CI -9.6 to 0.9
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.090 · Percentage difference: -3.5 · 95% CI -7.6 to 0.6
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.590 · Percentage difference: 1.8 · 95% CI -4.2 to 7.8
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.044 · Percentage difference: -3.7 · 95% CI -7.5 to -0.1
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.574 · Percentage difference: -1.4 · 95% CI -6.2 to 3.4
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.648 · Percentage difference: -1.2 · 95% CI -6.3 to 3.9
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.057 · Percentage difference: -6.2 · 95% CI -12.5 to 0.2
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.030 · Percentage difference: -3.7 · 95% CI -7.3 to -0.3
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.233 · Percentage difference: -2.5 · 95% CI -6.6 to 1.6
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.152 · Percentage difference: -1.8 · 95% CI -4.5 to 0.7
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.926 · Percentage difference: 0.3 · 95% CI -5.1 to 5.8
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.143 · Percentage difference: -3.9 · 95% CI -9.1 to 1.3
SecondaryGeometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 1 to Immediately Before 13vPnC Vaccination 1

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 1 to before Vaccination 1 were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 1 and 1 month after Vaccination 1 blood draws. Here, "n" signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 1 were analyzed.

Time frame:
Immediately before Vaccination 1, 1 month after Vaccination 1
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 1 to Immediately Before 13vPnC Vaccination 1
fold rise13vPnC+QIV/Placebo
Serotype 1 (n= 417)3.6 (3.20 to 4.14)
Serotype 3 (n= 419)3.4 (3.05 to 3.85)
Serotype 4 (n= 399)9.1 (7.33 to 11.18)
Serotype 5 (n= 422)3.0 (2.70 to 3.43)
Serotype 6A (n= 408)13.7 (11.30 to 16.62)
Serotype 6B (n= 391)8.9 (7.29 to 10.87)
Serotype 7F (n= 417)2.7 (2.40 to 2.98)
Serotype 9V (n= 405)2.1 (1.92 to 2.38)
Serotype 14 (n= 411)2.0 (1.78 to 2.30)
Serotype 18C (n= 417)4.0 (3.38 to 4.74)
Serotype 19A (n= 424)3.7 (3.20 to 4.28)
Serotype 19F (n= 419)4.2 (3.60 to 4.87)
Serotype 23F (n= 418)8.7 (7.07 to 10.61)
SecondaryGeometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 2 to Immediately Before 13vPnC Vaccination 2

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) 1 month after Vaccination 2 to before Vaccination 2 (1 month after Vaccination 1) were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before Vaccination 2 and 1 month after Vaccination 2 blood draws. Here, "number of participants analyzed" signifies total participants who were evaluable at this timepoint and "n" signifies participants with valid and determinate assay results for specified serotype at both the given visits. Number of participants who received at least 1 dose of 13vPnC during Vaccination 2 were analyzed.

Time frame:
Immediately before Vaccination 2, 1 month after Vaccination 2
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Pneumococcal Serotype-Specific Opsonophagocytic Activity (OPA) Titers 1 Month After 13vPnC Vaccination 2 to Immediately Before 13vPnC Vaccination 2
fold risePlacebo+QIV/13vPnC
Serotype 1 (n =413)3.6 (3.19 to 4.16)
Serotype 3 (n= 414)3.9 (3.47 to 4.42)
Serotype 4 (n= 391)10.4 (8.28 to 12.94)
Serotype 5 (n= 411)3.3 (2.87 to 3.72)
Serotype 6A (n= 399)17.9 (14.73 to 21.86)
Serotype 6B (n= 382)9.5 (7.69 to 11.67)
Serotype 7F (n= 407)2.7 (2.41 to 3.03)
Serotype 9V (n= 399)2.4 (2.12 to 2.71)
Serotype 14 (n= 406)2.3 (1.98 to 2.60)
Serotype 18C (n= 408)6.3 (5.21 to 7.51)
Serotype 19A (n= 416)4.6 (4.02 to 5.35)
Serotype 19F (n= 410)4.8 (4.12 to 5.69)
Serotype 23F (n= 412)12.9 (10.42 to 15.88)
SecondaryPercentage of Participants Achieving Seroconversion in Hemagglutination Inhibition Assay (HAI) Titers

Percentage of participants achieving seroconversion in HAI titers was defined as the percentage of participants with either before Vaccination 1 (pre-vaccination 1) HAI titer less than \<1:10 and after Vaccination 1 (post-vaccination 1) HAI titer \>=1:40 or before Vaccination 1 (pre-vaccination 1) HAI titer \>=1:10 and a minimum 4-fold rise in after Vaccination 1 (post-vaccination 1) HAI antibody titer with respect to before Vaccination 1 (pre-vaccination) titer for influenza virus strains. Here, "number of participants analyzed" signifies the participants who were evaluable at this timepoint.

Time frame:
Immediately before Vaccination 1, 1 month after Vaccination 1
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Seroconversion in Hemagglutination Inhibition Assay (HAI) Titers
percentage of participants13vPnC+QIV/PlaceboPlacebo+QIV/13vPnC
Strain: A/H1N129.3 (25.0 to 33.8)24.2 (20.2 to 28.5)
Strain: A/H3N227.9 (23.7 to 32.4)31.6 (27.3 to 36.3)
Strain: B/Brisbane21.3 (17.5 to 25.5)22.3 (18.5 to 26.6)
Strain: B/Massachusetts23.2 (19.3 to 27.5)24.7 (20.6 to 29.0)
Statistical analysis
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.094 · Percentage difference: 5.1 · 95% CI -0.9 to 11.0
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.232 · Percentage difference: -3.8 · 95% CI -9.9 to 2.4
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.734 · Percentage difference: -1.0 · 95% CI -6.6 to 4.5
  • 13vPnC+QIV/Placebo vs Placebo+QIV/13vPnC · Chan and Zhang method · p = 0.627 · Percentage difference: -1.5 · 95% CI -7.2 to 4.3
SecondaryGeometric Mean Fold Rise (GMFR) in Hemagglutination Inhibition Assay (HAI) 1 Month After Vaccination 1 to Immediately Before Vaccination 1

Fold rise 1 month after Vaccination 1 to before Vaccination 1 was calculated for each influenza virus strain (A/H1N1, A/H3N2, B/Brisbane and B/Massachusetts). GMFRs were calculated using all participants with available data from both the specified blood draws. CI for the GMFRs were back transformations of a CI based on the Student t distribution for mean fold rise. Here, "number of participants analyzed" signifies participants with valid and determinate assay results for specified strain at both the specified blood draws.

Time frame:
Immediately before Vaccination 1, 1 month after Vaccination 1
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) in Hemagglutination Inhibition Assay (HAI) 1 Month After Vaccination 1 to Immediately Before Vaccination 1
fold rise13vPnC+QIV/PlaceboPlacebo+QIV/13vPnC
Strain: A/H1N12.4 (2.17 to 2.64)2.2 (2.01 to 2.41)
Strain: A/H3N22.3 (2.09 to 2.51)2.4 (2.15 to 2.59)
Strain: B/Brisbane2.1 (1.97 to 2.32)2.2 (1.98 to 2.34)
Strain: B/Massachusetts2.2 (1.98 to 2.34)2.1 (1.98 to 2.30)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC+QIV/Placebo: After Vaccination 1—6/439 (1.4%)62/439 (14.1%)
Placebo+QIV/13vPnC: After Vaccination 1—0/437 (0%)52/437 (11.9%)
13vPnC+QIV/Placebo: After Vaccination 2—7/431 (1.6%)42/431 (9.7%)
Placebo+QIV/13vPnC: After Vaccination 2—6/432 (1.4%)51/432 (11.8%)
13vPnC+QIV/Placebo: After 13vPnC Vaccination—6/439 (1.4%)62/439 (14.1%)
Placebo+QIV/13vPnC: After 13vPnC Vaccination—6/432 (1.4%)51/432 (11.8%)
13vPnC+QIV/Placebo: at 6-Month Follow-up—5/439 (1.1%)6/439 (1.4%)
Placebo+QIV/13vPnC: at 6-Month Follow-up—6/437 (1.4%)6/437 (1.4%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
Event13vPnC+QIV/Placebo: After Vaccination 1Placebo+QIV/13vPnC: After Vaccination 113vPnC+QIV/Placebo: After Vaccination 2Placebo+QIV/13vPnC: After Vaccination 213vPnC+QIV/Placebo: After 13vPnC VaccinationPlacebo+QIV/13vPnC: After 13vPnC Vaccination13vPnC+QIV/Placebo: at 6-Month Follow-upPlacebo+QIV/13vPnC: at 6-Month Follow-up
Myocardial infarctionCardiac disorders0/4390/4372/4310/4320/4390/4320/4390/437
PneumoniaInfections and infestations0/4390/4370/4310/4320/4390/4320/4392/437
CellulitisInfections and infestations1/4390/4371/4310/4321/4390/4320/4390/437
Cardiogenic shockCardiac disorders0/4390/4371/4310/4320/4390/4320/4390/437
DyspepsiaGastrointestinal disorders0/4390/4371/4310/4320/4390/4320/4390/437
VomitingGastrointestinal disorders0/4390/4371/4310/4320/4390/4320/4390/437
OsteomyelitisInfections and infestations0/4390/4371/4310/4320/4390/4320/4390/437
HyperhidrosisSkin and subcutaneous tissue disorders0/4390/4371/4310/4320/4390/4320/4390/437
Cardiac failure congestiveCardiac disorders0/4390/4370/4311/4320/4391/4320/4390/437
Coronary artery diseaseCardiac disorders0/4390/4370/4311/4320/4391/4320/4390/437
Most frequent other events
Showing 10 of 135
Most frequent other events
Event13vPnC+QIV/Placebo: After Vaccination 1Placebo+QIV/13vPnC: After Vaccination 113vPnC+QIV/Placebo: After Vaccination 2Placebo+QIV/13vPnC: After Vaccination 213vPnC+QIV/Placebo: After 13vPnC VaccinationPlacebo+QIV/13vPnC: After 13vPnC Vaccination13vPnC+QIV/Placebo: at 6-Month Follow-upPlacebo+QIV/13vPnC: at 6-Month Follow-up
Injection site painGeneral disorders8/4392/4370/4313/4328/4393/4320/4390/437
Upper respiratory tract infectionInfections and infestations8/4394/4373/4314/4328/4394/4320/4390/437
Urinary tract infectionInfections and infestations5/4391/4372/4314/4325/4394/4320/4390/437
BronchitisInfections and infestations3/4394/4374/4314/4323/4394/4320/4390/437
NasopharyngitisInfections and infestations3/4393/4374/4311/4323/4391/4320/4390/437
FallInjury, poisoning and procedural complications0/4391/4374/4312/4320/4392/4321/4390/437
HeadacheNervous system disorders0/4393/4374/4312/4320/4392/4320/4390/437
SinusitisInfections and infestations2/4392/4371/4314/4322/4394/4320/4390/437
PyrexiaGeneral disorders0/4394/4370/4311/4320/4391/4320/4390/437
NauseaGastrointestinal disorders0/4391/4373/4313/4320/4393/4320/4390/437

Baseline characteristics

Safety population included all participants who received at least 1 dose of vaccination.

Age, Continuous
Age, Continuous(years)13vPnC+QIV/PlaceboPlacebo+QIV/13vPnCTotal
Mean66.9 ± 966.4 ± 8.8566.7 ± 8.93
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC+QIV/PlaceboPlacebo+QIV/13vPnCTotal
Female234249483
Male205188393
08

Study locations

44 sites
  • Achieve Clinical Research, LLC
    Birmingham, Alabama 35216, United States
  • Optimal Research (Formerly Accelovance)
    Huntsville, Alabama 35802, United States
  • Radiant Research, Inc.
    Scottsdale, Arizona 85251, United States
  • Kaiser Permanente Vaccine Study Center
    Oakland, California 94612, United States
  • Kaiser Permanante South. Sacramento
    Sacramento, California 95823, United States
  • Benchmark Research
    San Francisco, California 94108, United States
  • Kaiser Pemanente Santa Clara
    Santa Clara, California 95051, United States
  • Avail Clinical Research, LLC
    DeLand, Florida 32720, United States
  • Westside Center for Clinical Research
    Jacksonville, Florida 32205, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Radiant Research, Inc.
    Pinellas Park, Florida 33781, United States
  • Meridian Clinical Research
    Savannah, Georgia 31406, United States
  • Optimal Research, LLC
    Mishawaka, Indiana 46545, United States
  • Clinical Research Advantage, Inc/Ridge Family Practice
    Council Bluffs, Iowa 51503, United States
  • Johnson County Clin-Trials, Inc.
    Lenexa, Kansas 66219, United States
  • Benchmark Research
    Metairie, Louisiana 70002, United States
  • Meridian Clinical Research
    Bellevue, Nebraska 68005, United States
  • Meridian Clinical Research
    Norfolk, Nebraska 68701, United States
  • Meridian Clinical Research, LLC
    Omaha, Nebraska 68134, United States
  • Clinical Research Center of Nevada, LLC
    Las Vegas, Nevada 89104, United States
  • Clinical Research Advantage, Inc.
    Las Vegas, Nevada 89128, United States
  • United Medical Associates
    Binghamton, New York 13901, United States
  • Regional Clinical Research, Inc.
    Endwell, New York 13760, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • PMG Research of Raleigh, LLC d/b/a PMG Research of Cary
    Cary, North Carolina 27518, United States
  • PharmQuest
    Greensboro, North Carolina 27408, United States
  • PMG Research of Hickory, LLC
    Hickory, North Carolina 28602, United States
  • Clinical Trials of America, Inc.
    Winston-Salem, North Carolina 27103, United States
  • PMG Research of Winston-Salem
    Winston-Salem, North Carolina 27103, United States
  • Radiant Research, Inc
    Columbus, Ohio 43212, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • Preferred Primary Care Physicians, Inc.
    Carnegie, Pennsylvania 15106, United States
  • Brandywine Clinical Research
    Downingtown, Pennsylvania 19335, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • PMG Research of Charleston
    Mt. Pleasant, South Carolina 29464, United States
  • Internal Medicine and Pediatric Associates of Bristol, PC
    Bristol, Tennessee 37620, United States
  • Volunteer Research Group
    Knoxville, Tennessee 37920, United States
  • Benchmark Research
    Austin, Texas 78705, United States
  • Benchmark Research
    Fort Worth, Texas 76735, United States
  • Diagnostics Research Group
    San Antonio, Texas 78229, United States
  • Radiant Research, Inc.
    Murray, Utah 84123, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • J. Lewis Research, Inc. / Jordan River Family Medicine
    South Jordan, Utah 84095, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2014
First posted
Apr 28, 2014
Start
Sep 2014
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Jul 1, 2016
Last update
Jul 1, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02124161
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 28, 2014
Start date
Sep 2014
Primary completion
May 2015
Completion
May 2015
Results posted
Jul 1, 2016
Last update
Jul 1, 2016

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion